DOP2022000129A - Anticuerpos contra la integrina alfa 11 beta 1 - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1

Info

Publication number
DOP2022000129A
DOP2022000129A DO2022000129A DO2022000129A DOP2022000129A DO P2022000129 A DOP2022000129 A DO P2022000129A DO 2022000129 A DO2022000129 A DO 2022000129A DO 2022000129 A DO2022000129 A DO 2022000129A DO P2022000129 A DOP2022000129 A DO P2022000129A
Authority
DO
Dominican Republic
Prior art keywords
beta
antibodies against
integrin alpha
against integrin
antigen
Prior art date
Application number
DO2022000129A
Other languages
English (en)
Inventor
Kurtagic Elma
W Iii Meador James
Jr Beneduce Christopher
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of DOP2022000129A publication Critical patent/DOP2022000129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción incluye anticuerpos que se unen específicamente a la integrina alfa 11 beta 1 (a11ß1), así como métodos de elaboración y uso de esos anticuerpos. En algunas modalidades, un anticuerpo anti-a11p1, o un fragmento de unión al antígeno de este, es un anticuerpo monoclonal, o un fragmento de unión al antígeno de este. La presente descripción también proporciona el uso de esos anticuerpos para tratar cánceres y/o trastornos fibróticos.
DO2022000129A 2019-12-20 2022-06-17 Anticuerpos contra la integrina alfa 11 beta 1 DOP2022000129A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
DOP2022000129A true DOP2022000129A (es) 2022-10-31

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000129A DOP2022000129A (es) 2019-12-20 2022-06-17 Anticuerpos contra la integrina alfa 11 beta 1

Country Status (17)

Country Link
US (1) US20230050972A1 (es)
EP (1) EP4076525A4 (es)
JP (1) JP2023508286A (es)
KR (1) KR20220123013A (es)
CN (1) CN115135342A (es)
AU (1) AU2020407124A1 (es)
BR (1) BR112022012093A2 (es)
CA (1) CA3165386A1 (es)
CL (1) CL2022001673A1 (es)
CO (1) CO2022010204A2 (es)
CR (1) CR20220288A (es)
DO (1) DOP2022000129A (es)
EC (1) ECSP22056627A (es)
IL (1) IL294047A (es)
MX (1) MX2022007521A (es)
PE (1) PE20221723A1 (es)
WO (1) WO2021127500A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303741A (en) * 2020-12-18 2023-08-01 Momenta Pharmaceuticals Inc Antibodies against integrin alpha 11 in cell 1
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2023250415A2 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
WO2008075045A1 (en) * 2006-12-18 2008-06-26 Cartela R & D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
JP7440718B2 (ja) * 2018-03-01 2024-02-29 恭之 横崎 抗インテグリンα１１モノクローナル抗体、およびその利用

Also Published As

Publication number Publication date
CN115135342A (zh) 2022-09-30
CO2022010204A2 (es) 2022-10-21
WO2021127500A1 (en) 2021-06-24
ECSP22056627A (es) 2022-11-30
US20230050972A1 (en) 2023-02-16
CR20220288A (es) 2022-10-07
IL294047A (en) 2022-08-01
MX2022007521A (es) 2022-07-19
EP4076525A1 (en) 2022-10-26
WO2021127500A9 (en) 2021-07-29
CL2022001673A1 (es) 2023-02-03
CA3165386A1 (en) 2021-06-24
EP4076525A4 (en) 2024-05-01
KR20220123013A (ko) 2022-09-05
PE20221723A1 (es) 2022-11-04
JP2023508286A (ja) 2023-03-02
BR112022012093A2 (pt) 2022-08-30
AU2020407124A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
CL2020001974A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos. (divisional solicitud 201903093)
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2019012200A2 (es) Anticuerpos anti-cd33 y métodos para utilizarlos
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
AR119295A1 (es) Moléculas de unión a antígeno ligantes de cea
PE20210186A1 (es) Anticuerpos anti-sortilina y metodos para su uso
ECSP21022299A (es) Anticuerpos de anti-cd33 y métodos para usarlos
ECSP22055004A (es) Anticuerpos anti?mertk y m?todos de uso de los mismos
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CO2021015254A2 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
CO2021000386A2 (es) Anticuerpos humanizados contra psma
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora
CO2021009689A2 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
BR112022009611A2 (pt) Anticorpos anti-ror-2 e métodos de uso
BR112023020574A2 (pt) Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos
AR119982A1 (es) Terapias de combinación con anticuerpos entpd2
BR112021020612A2 (pt) Métodos para tratamento de sujeitos com artrite psoriática